Spyre Therapeutics, Inc. (SYRE) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Spyre Therapeutics, Inc. (SYRE) Healthcare & Pipeline Overview

Spyre Therapeutics, Inc. is a preclinical-stage biotechnology firm specializing in innovative treatments for inflammatory bowel disease (IBD). The company's pipeline features monoclonal antibody candidates like SPY001, SPY002, and SPY120, all in preclinical stages, positioning it as a potential disruptor in the IBD therapeutics market.

What Is the Investment Thesis for SYRE?

Spyre Therapeutics presents a high-risk, high-reward investment opportunity due to its focus on novel IBD therapeutics. The company's pipeline of monoclonal antibody candidates, particularly SPY001, SPY002, and SPY120, targets validated IBD pathways. A successful transition from preclinical to clinical stages, with positive Phase 1 trial results, could significantly increase the company's valuation. However, the company's current market capitalization of $6.05B reflects considerable optimism, given its preclinical status and negative profit margin of -198.3%. Key value drivers include successful IND filings, positive clinical trial data, and potential partnerships with larger pharmaceutical companies. The high beta of 2.94 indicates significant volatility, making it suitable for investors with a high-risk tolerance.

Based on FMP financials and quantitative analysis

SYRE Key Highlights

• Market capitalization of $6.05B, reflecting investor confidence in its pipeline.
• Profit margin of -198.3%, indicative of a preclinical stage company with significant R&D expenses.
• Beta of 2.94, suggesting high volatility compared to the overall market.
• Focus on inflammatory bowel disease (IBD), a market with significant unmet needs.
• Pipeline includes multiple monoclonal antibody candidates targeting different IBD pathways.

Who Are SYRE's Competitors?

SYRE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SYRE's Key Strengths?

• Novel pipeline of monoclonal antibody candidates.
• Focus on combination therapies targeting multiple IBD pathways.
• Experienced management team with expertise in drug development.
• Strong intellectual property position.

What Are SYRE's Weaknesses?

• Preclinical stage company with no approved products.
• High cash burn rate due to R&D expenses.
• Reliance on successful clinical trial outcomes.
• Limited financial resources compared to larger pharmaceutical companies.

What Could Drive SYRE Stock Higher?

• IND filing for SPY001 in the next 12-18 months.
• Preclinical data releases for SPY002 and SPY120 in the next 6-12 months.
• Advancement of early-stage programs (SPY003, SPY004, SPY130, SPY230) through preclinical studies.
• Potential strategic partnerships with larger pharmaceutical companies.

What Are the Key Risks for SYRE?

• Negative return on equity (-31.2%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $407.9M recently.
• Clinical trial failures for SPY001, SPY002, or SPY120.
• Regulatory delays or rejection of IND filings.
• Competition from established pharmaceutical companies with approved IBD therapies.
• High cash burn rate and need for additional financing.
• Patent expiration and biosimilar competition in the future.

What Are the Growth Opportunities for SYRE?

• Advancement of SPY001 to Clinical Trials: SPY001, targeting the α4β7 integrin, represents a significant growth opportunity if it successfully transitions into clinical trials. The IBD market, including ulcerative colitis and Crohn's disease, is estimated to reach $20 billion by 2028. Positive Phase 1 data could lead to partnerships and further investment, driving significant value for Spyre. The timeline for this advancement is projected within the next 12-18 months.
• Development of SPY002 and SPY120: SPY002, targeting TL1A, and SPY120, a combination of anti-α4β7 and anti-TL1A antibodies, offer potential synergistic effects in treating IBD. The TL1A pathway has gained increasing attention as a key driver of fibrosis and inflammation in IBD. Successful preclinical development and subsequent clinical trials could open up a new avenue for IBD treatment. This development is expected to unfold over the next 2-3 years.
• Expansion of Pipeline with SPY003, SPY004, SPY130, and SPY230: Spyre's early-stage programs, including SPY003 (anti-IL-23 mAb), SPY004 (novel MOA mAb), SPY130 (anti-α4β7 and anti-IL-23 mAbs), and SPY230 (anti-TL1A and anti-IL-23 mAbs), represent long-term growth opportunities. These programs target different aspects of the IBD pathogenesis and could lead to the development of a diverse portfolio of IBD therapeutics. These programs are in early stages, with potential clinical trials 3-5 years out.
• Strategic Partnerships and Acquisitions: Spyre could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its IBD therapeutics. The biotechnology industry is characterized by collaborations and acquisitions, and Spyre's innovative pipeline could make it an attractive target. Such partnerships could provide financial resources and expertise, enhancing Spyre's growth prospects. This is an ongoing opportunity dependent on pipeline progress and market conditions.
• Focus on Combination Therapies: Spyre's strategy of developing combination therapies, such as SPY120 and SPY230, offers a competitive advantage. Combination therapies have the potential to address multiple disease pathways simultaneously, leading to more effective treatment outcomes. The market for combination therapies in IBD is growing, driven by the need for more comprehensive treatment approaches. This strategy could differentiate Spyre from competitors focusing on single-target therapies. This is an ongoing strategy that will continue to evolve as the pipeline progresses.

What Opportunities Does SYRE Have?

• Strategic partnerships with larger pharmaceutical companies.
• Positive clinical trial data leading to increased valuation.
• Expansion of pipeline with new therapeutic candidates.
• Growing market for IBD therapeutics.

What Threats Does SYRE Face?

• Clinical trial failures.
• Competition from established pharmaceutical companies.
• Regulatory hurdles and delays.
• Patent expiration and biosimilar competition.

What Are SYRE's Competitive Advantages?

• Proprietary monoclonal antibody technology.
• Focus on novel IBD targets and combination therapies.
• Strong intellectual property portfolio.
• Expertise in preclinical drug development.

What Does SYRE Do?

Spyre Therapeutics, Inc., founded in 2013 and based in Waltham, Massachusetts, is a biotechnology company focused on developing novel therapeutics for patients suffering from inflammatory bowel disease (IBD). Formerly known as Aeglea BioTherapeutics, Inc., the company rebranded in November 2023 to reflect its strategic shift towards IBD therapies. Spyre's lead product candidate, SPY001, is a human monoclonal immunoglobulin G1 antibody designed to selectively bind to the α4β7 integrin, a key target for treating ulcerative colitis and Crohn's disease. The company is also developing SPY002, a human monoclonal antibody (mAb) candidate targeting tumor necrosis factor-like ligand 1A (TL1A), and SPY120, a combination of SPY001 (anti-α4β7) and SPY002 (anti-TL1A) antibodies. These candidates are currently in preclinical studies. Additionally, Spyre has several early-stage programs, including SPY003 (anti-IL-23 mAb), SPY004 (a novel mechanism of action mAb), SPY130 (a combination of anti-α4β7 and anti-IL-23 mAbs), and SPY230 (a combination of anti-TL1A and anti-IL-23 mAbs). Spyre's strategy centers on creating targeted therapies that address the underlying causes of IBD, offering potential improvements over existing treatments.

What Products and Services Does SYRE Offer?

• Develops therapeutics for inflammatory bowel disease (IBD).
• Focuses on monoclonal antibody-based therapies.
• Targets key IBD pathways such as α4β7 integrin and TL1A.
• Conducts preclinical research and development.
• Aims to create novel treatments for ulcerative colitis and Crohn's disease.
• Explores combination therapies to address multiple disease pathways.
• Seeks to improve outcomes for patients living with IBD.

How Does SYRE Make Money?

• Develops and patents novel therapeutic candidates.
• Out-licenses or partners with larger pharmaceutical companies for clinical development and commercialization.
• Raises capital through equity financing to fund research and development activities.
• Focuses on preclinical research and early-stage clinical trials.

What Industry Does SYRE Operate In?

Spyre Therapeutics operates within the competitive biotechnology industry, specifically targeting the inflammatory bowel disease (IBD) market. This market is characterized by a high unmet need for more effective and targeted therapies. The IBD market is projected to grow, driven by increasing prevalence and a growing understanding of the disease's underlying mechanisms. Competitors include established pharmaceutical companies and other biotech firms developing novel IBD treatments. Spyre's focus on monoclonal antibody combinations and novel mechanisms of action positions it to potentially capture a significant share of this expanding market.

Who Are SYRE's Key Customers?

• Patients with inflammatory bowel disease (IBD).
• Pharmaceutical companies seeking to expand their IBD therapeutic portfolios.
• Healthcare providers who treat patients with IBD.
• Potential partners for licensing and collaboration agreements.

Net sellingInsider Activity

Over the past six months, Spyre Therapeutics, Inc. insiders filed 30 SEC Form 4 transactions — 24 sales and 6 purchases. On net that is roughly 4.1M shares disposed (about $407.9M), a signal worth weighing alongside the fundamentals.

ROE -31%Key Financial Metrics

Return on equity for Spyre Therapeutics, Inc. stands at -31.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -23.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.97 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.6%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Spyre Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 37.12 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Spyre Therapeutics, Inc. revenue of about $89K for fiscal 2026, with EPS near $-3.01. The estimate reflects 7 contributing analysts.

SYRE Valuation & Market Position

With a $6.05B market cap, Spyre Therapeutics, Inc. sits in the mid-cap segment of the market. Relative to its peer group, SYRE's quantitative score of 24/100 is below the peer average of 87/100.

SYRE Financials

SYRE Latest News

SYRE Analyst Consensus

SYRE MoonshotScore

Latest Spyre Therapeutics, Inc. Analysis

What Investors Ask About Spyre Therapeutics, Inc. (SYRE) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources